Avenue Biosciences Holding
Menlo Park, US · Founded 2023 · Delaware corporation
Founders & leadership
KR
Katja RostiExecutive
TA
Tero-Pekka AlastaloNamed on SEC filing
Board
JE
Jenny EngerfeltBoard director
GP
Gabriel PoteliunaiteBoard director
Reported raises · per SEC filings
Form D private placements$7.4M disclosed across 1 round · 2025
▶$7.4MraisedJan 2026 · 12 investors · BiotechnologyRule 506(c)
▶$7.4MraisedJan 2026 · 12 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jenny EngerfeltDirector
- Gabriel PoteliunaiteDirector
- Katja RostiExecutive Officer, Director
- Tero-Pekka AlastaloExecutive Officer, Director
- Offering amount
- $8.4M
- Amount sold
- $7.4M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Avenue Biosciences Holding raised?
- Avenue Biosciences Holding has disclosed $7.4M raised across 1 round.
- Where is Avenue Biosciences Holding headquartered?
- Avenue Biosciences Holding is headquartered in Menlo Park, US.